Effect of rosuvastatin on fasting and postprandial endothelial biomarker levels and microvascular reactivity in patients with type 2 diabetes and dyslipidemia: a preliminary report

The cardiovascular benefits of statins have been proven, but their effect on circulation in small vessels has not been examined fully. We investigated the effect of 20  mg rosuvastatin on biomarkers, including ...
Source: Cardiovascular Diabetology - Category: Cardiology Authors: Tags: Original investigation Source Type: research

Related Links:

IgE to the Mammalian Oligosaccharide Galactose-α-1,3-Galactose Is Associated With Increased Atheroma Volume and Plaques With Unstable Characteristics. Arterioscler Thromb Vasc Biol. 2018 Jun 14;: Authors: Wilson JM, Nguyen AT, Schuyler AJ, Commins SP, Taylor AM, Platts-Mills TAE, McNamara CA Abstract OBJECTIVE: Emerging evidence suggests a link between coronary artery disease and type 2 immunity. We sought to test the hypothesis that IgE sensitization to the mammalian oligosaccharide galactose-α-1,3-galactose (α-Gal)-the target allergen of delayed anaphylaxis to red meat-is associate...
Source: Arteriosclerosis, Thrombosis and Vascular Biology - Category: Cardiology Authors: Tags: Arterioscler Thromb Vasc Biol Source Type: research
(University of Arizona Health Sciences) Some people who take statins to lower cholesterol have a slightly higher risk of developing type 2 diabetes. Genetic epidemiologist Yann Klimentidis, Ph.D., at the UA Mel and Enid Zuckerman College of Public Health received a $1.1 million grant from the National Institutes of Health to study the connection between type 2 diabetes and cardiovascular disease.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news
This study was a prospective trial in 12 family medicine offices cluster randomized to either the intervention or usual care. The intervention was delivered for 12 months, and subjects had research visits at baseline and 12 months. The primary outcome was adherence to guidelines, and secondary outcomes included changes in key cardiovascular risk factors and preventative health measures. We enrolled 302 subjects. There was no improvement in the Guideline Advantage score from baseline to 12 months in the control group (64.7% versus 63.1%, respectively; P=0.21). There was a statistically significant improvement in the interve...
Source: Circulation: Cardiovascular Quality and Outcomes - Category: Cardiology Authors: Tags: Cardiovascular Disease, Diabetes, Type 2, Lifestyle, Secondary Prevention, Health Services Original Articles Source Type: research
Abstract Leptin, an adipokine that is implicated in the control of food intake via appetite suppression, may also stimulate oxidative stress, inflammation, thrombosis, arterial stiffness, angiogenesis and atherogenesis. These leptin-induced effects may predispose to the development of cardiovascular diseases. In the present review we discuss the evidence linking leptin levels with the presence, severity and/or prognosis of both coronary artery disease and non-cardiac vascular diseases such as stroke, carotid artery disease, peripheral artery disease (PAD) and abdominal aortic aneurysms (AAA) as well as with chroni...
Source: Acta Pharmacologica Sinica - Category: Drugs & Pharmacology Authors: Tags: Acta Pharmacol Sin Source Type: research
In conclusion, DD is a major health problem worldwide. It is a significant CVD risk factor and should be treated according to current guidelines. The means today exist to normalize all quantitative, qualitative, and kinetic aberrations of DD, thereby reducing CVD risk. PMID: 29858856 [PubMed - in process]
Source: Hormones - Category: Endocrinology Tags: Hormones (Athens) Source Type: research
CONCLUSION: The combination of metformin with SGLT2i, GLP-1 RA, and a potent statin, in high CVD risk patients with DM, is expected to substantially reduce CVD mortality and morbidity, improving the quality of life of patients with DM at the same time. Prospective studies are needed to confirm this finding. PMID: 29865997 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - Category: Drugs & Pharmacology Authors: Tags: Curr Pharm Des Source Type: research
The relevance of low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (non-HDL-C) goals for primary prevention of ASCVD among patients with diabetes was assessed. This retrospective cohort study included individuals with type 2 diabetes, age 21-90 years, taking statins, with no history of ASCVD as of January 1, 2006, in Kaiser Permanente Northern California (KPNC), an integrated healthcare delivery system. Multivariate cox models were utilized to estimate hazard ratios (HRs) for incident ASCVD events by achieved LDL-C and non-HDL-C levels with adjustment for potential confounders.
Source: The American Journal of Cardiology - Category: Cardiology Authors: Source Type: research
ConclusionsRhabdomyolysis is a rare but serious complication due to lipid-lowering therapy with statins and fibrates. Treating physicians should be aware and patients should be warned to report about muscle symptoms after starting statins or fibrates. Rhabdomyolysis may occur with mild symptoms and signs and may occur later, even after discontinuation of the drug.
Source: Journal of Medical Case Reports - Category: General Medicine Source Type: research
In conclusion, the connection between DNA damage and aging is emphasized by the secretion of senescence-associated proteins during cellular senescence, a phenotype which is activated by DNA damage and is common for both human and mice. Though much progress has been achieved, full understanding of these mechanisms has still a long way to go. XPO1 as a Novel Target for Therapies to Enhance Autophagy https://www.fightaging.org/archives/2018/05/xpo1-as-a-novel-target-for-therapies-to-enhance-autophagy/ Autophagy is the name given to a collection of cellular housekeeping processes that recycle damaged and un...
Source: Fight Aging! - Category: Research Authors: Tags: Newsletters Source Type: blogs
This article is protected by copyright. All rights reserved. PMID: 29737015 [PubMed - as supplied by publisher]
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Tags: Clin Pharmacol Ther Source Type: research
More News: Cardiology | Cardiovascular | Cholesterol | Crestor | Diabetes | Diabetes Type 2 | Endocrinology | Heart | Rosuvastatin | Statin Therapy